(Q21261946)

Dimensions Publication ID

Dimensions

1043532394

22 August 2022

Gerald I Polukoff

series ordinal

2

author given names

Gerald I

author last names

Polukoff

1 reference

Dimensions Publication ID

Dimensions

1043532394

BMC Cardiovascular Disorders

22 August 2022

language of work or name

English

0 references

publication date

11 June 2003

0 references

published in

0 references

volume

3

0 references

page(s)

5

0 references

issue

1

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2261-3-5

0 references

cites work

Appetite suppressants and valvular heart disease - a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Appetite suppressants and valvular heart disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Valvular heart disease associated with fenfluramine-phentermine

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Appetite suppressants and valvular heart disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

The fen-phen finale: a study of weight loss and valvular heart disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5

Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5

Use of prescription weight loss pills among U.S. adults in 1996-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5

Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=194859

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months

29 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5

Underestimation of the valvulopathy effect of fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2261-3-5